Previous 10 | Next 10 |
The following slide deck was published by AVROBIO, Inc. in conjunction with this Read more ...
Avrobio (AVRO) recently reported impressive data for its gene therapy in Fabry's disease (see the table below). Fabry’s disease o verview Fabry’s disease is the most common lysosomal storage disease. It is an X-linked inborn error due to mutations in the alpha-Gal-A ge...
AVROBIO, Inc . (NASDAQ:AVRO) a Phase 2 clinical-stage gene therapy company, today announced that members of its senior management team are scheduled to participate in five upcoming investor conferences. Citi’s 14th Annual Biotech Conference Date: Wednesday, September 4, 2019 L...
AVROBIO, Inc . (NASDAQ: AVRO) (“AVROBIO” or the “Company”), a Phase 2 clinical-stage gene therapy company, today announced the appointment of Georgette Verdin as Chief Human Resources Officer (CHRO). Ms. Verdin will be responsible for all aspects of human resource...
The following slide deck was published by AVROBIO, Inc. in conjunction with this Read more ...
AVROBIO, Inc. (NASDAQ: AVRO) (“AVROBIO” or the “Company”), a Phase 2 clinical-stage gene therapy company, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside of the Company’s 2018 Stock Option ...
AVROBIO (NASDAQ: AVRO ): Q2 GAAP EPS of -$0.67 beats by $0.09 . More news on: AVROBIO, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Reported positive interim results from clinical trials of AVR-RD-01 investigational gene therapy in Fabry disease, including 87% substrate reduction in first kidney biopsy at one year post-treatment On track to dose first patients in Phase 1/2 clinical trials for Gaucher and cystinosis...
AVROBIO, Inc . (NASDAQ:AVRO), a Phase 2 clinical-stage gene therapy company, today announced that the Company will present at the 2019 Wedbush PacGrow Healthcare Conference on Wednesday, August 14, 2019, at 2:30 p.m. ET at the Parker New York Hotel in New York City. Geoff MacKay, AVROBIO...
Gainers: PRCP +12.2% . PHM +1.8% . AVRO +1.5% . More news on: Perceptron, Inc., PulteGroup, Inc., AVROBIO, Inc., Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
2024-06-20 09:02:05 ET AvroBio Inc (AVRO) announced stock split at a ratio of 1-for-12 on 2024-06-21 ... Full story available on KlickAnalytics.com
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
Swire Pacific Ltd. ADR (Class A) (SWRAY) is expected to report for Q4 2023 Troika Media Group Inc. (TRKAQ) is expected to report for quarter end 2023-12-31 American Environmental Partners Inc. (AEPT) is expected to report for quarter end 2023-12-31 Veolia Environnement S.A. ADR (VEOEY...